Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-GIO study of esomeprazole effects on afatinib pharmacokinetics in EGFR-mutated NSCLC
NL-OMON45272Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of afatinib and esomeprazole in non-small cell lung cancer (NSCLC), sponsored by Erasmus MC. Primary endpoint: Afatinib area under the concentration-time curve. Started Aug 2017; status: active, not recruiting.
02
Drugs
afatinibesomeprazole
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON45272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45272.